PALI NASDAQ
Palisade Bio, Inc.
1W: +5.2%
1M: +6.9%
3M: +3.1%
YTD: -19.2%
1Y: +74.1%
3Y: -93.7%
5Y: -99.9%
$2.02
-0.01 (-0.49%)
Weekly Expected Move ±13.2%
$1
$2
$2
$2
$2
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Bullish
75
Insider+$0.2M
Congress—
ETF Holdings—
Key Statistics
Market Cap$350.6M
52W Range0.53-2.86
Volume1,793,973
Avg Volume3,443,232
Beta1.51
Dividend—
Analyst Ratings
Company Info
CEOJ. D. Finley
Employees14
SectorHealthcare
IndustryBiotechnology
IPO Date2007-03-30
Websitepalisadebio.com
5800 Armada Drive
Denver, CA 92008
US
Denver, CA 92008
US
858 704 4900
About Palisade Bio, Inc.
Palisade Bio, Inc. is a clinical-stage biopharmaceutical firm dedicated to identifying, advancing, and bringing to market orally administered treatments for significant conditions stemming from a compromised gastrointestinal mucosal barrier. The company's primary therapeutic candidate, LB1148, is an oral liquid formulation designed to inhibit digestive enzymes. Its goal is to safeguard gut integrity when the intestine experiences stress due to factors such as diminished blood supply, infections, or surgical procedures. Established in 2005, the company maintains its headquarters in Carlsbad, California.
Latest News
Verra Mobility, Zscaler, Box And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
Brookline Capital Markets Predicts Palisade Bio Q1 Earnings
Brokers Issue Forecasts for Palisade Bio Q3 Earnings
Wolfe Highlights Differentiation Potential in Palisade Bio, Inc. (PALI) Clinical Profile
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Baltera Robert Jr. | P-Purchase | 25,000 | $1.96 | 2026-07-09 |
| Baltera Robert Jr. | P-Purchase | 20,000 | $1.99 | 2026-07-08 |
| Baltera Robert Jr. | P-Purchase | 30,000 | $2.03 | 2026-07-07 |
| Jones Mitchell Lawre | S-Sale | 51,880 | $2.05 | 2026-07-07 |
| Finley John David | S-Sale | 146,798 | $2.07 | 2026-07-07 |